VOLITIONRX LTD

VolitionRx Limited is a multi-national epigenetics company that develops blood-based tests to detect and monitor cancer and diseases associated with NETosis, such as sepsis. Its patented technologies, including Nu.Q and Capture-PCR/Capture-Seq, analyze circulating nucleosomes, transcription factors, and tumor-derived DNA in the blood to identify disease changes at early stages. The company's key product pillars encompass Nu.Q Vet for canine cancer screening and companion animal diagnostics, Nu.Q NETs for conditions linked to NETosis, Nu.Q Discover for nucleosome profiling in drug research, and Nu.Q Cancer for human oncology detection and monitoring. Volition serves veterinarians, pet owners, academic institutions, diagnostic providers, and pharmaceutical researchers.

The company operates a purpose-built 17,000 square foot laboratory and 10,000 square foot manufacturing facility in Gembloux, Belgium, alongside an innovation lab and offices in California, London, and Nevada. It employs 75 full-time equivalent staff members, and its canine cancer test is available across more than twenty countries. VolitionRx maintains its principal executive office in Henderson, Nevada.

Summary of the business section of Volitionrx's latest annual report, written by StockData.

“As of December 31, 2025, we had 75 full-time equivalent (“FTE”) personnel compared to 85 as of December 31, 2024, reflecting the need to prioritize the cash utilization in our commercial and production activities.”